Boegemann, Martin

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Seifert, R., Kessel, K., Schlack, K., Weber, M., Herrmann, K., Spanke, M., Fendler, W. P., Hadaschik, B., Kleesiek, J., Schäfers, M., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 160